News
Mesoblast Limited receives ethics approval to treat COVID-19 patients in Australia
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that it has received ethics approval to include Australian hospitals in thePhase 3 randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome...
News
Delivery of COVID-19 vaccine: DHL study shows how public and private sector can partner for success
With first emergency use authorizations for COVID-19 vaccines expected to be effective in the last quarter of 2020, logistics providers are challenged to rapidly establish medical supply chains to deliver serums of unparalleled amounts of more than ten billion...
Clinical Trials
Bharat Biotech gets approval to conduct phase 2 trials of COVID-19 vaccine Covaxin
Hyderabad-based Bharat Biotech has received approval to conduct phase II trials of its COVID-19 vaccine Covaxin from September 7.
The Directorate General of Health Service said in a statement: "This is to inform you that the subject proposal was examined...
Clinical Trials
Early trials find Russia’s Sputnik V safe, volunteers develop coronavirus antibodies within 3 weeks
Much buzz was created around the world when Russia claimed to have approved the first COVID-19 vaccine around the world, for public use. Experts and researchers from around the world questioned the efficacy and safety of the vaccine, dubbed...
News
CureVac to Receive 252million Euros to Support COVID-19 Vax Development
CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) in clinical trials, has received notification from the German Federal Ministry of Education and Research (BMBF) that CureVac is expected receive...
News
World’s Largest Virtual Pharma Expo Agenda Unveiled
CPhI Festival of Pharma (5-16 October, 2020), the world’s largest ever virtual pharma expo, unveils its ground-breaking two-week long agenda. The newly launched and rapidly created virtual event will provide the global pharma community with a vital platform to...
News
Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg
Bristol Myers Squibb announced that the U.S. FDA has approved Onureg® (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or CR with incomplete blood...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read